Intervention not reported
Quality of life (Asthma Quality of Life Questionnaire, with 32 items, 0 to 7 points per item) · People with asthma (mostly mild or moderate)
1 finding from 1 review
Intervention not reported
Asthma symptoms (different severity scores; change from baseline) · People with asthma (mostly mild or moderate)
1 finding from 1 review
Intervention not reported
Asthma control (weekly number of attacks) · People with asthma (mostly mild or moderate)
1 finding from 1 review
Intervention not reported
Forced expiratory volume in one second (change from baseline FEV1 (L)) · People with asthma (mostly mild or moderate)
1 finding from 1 review
Intervention not reported
Reduced asthma medication usage · People with asthma (mostly mild or moderate)
The intervention may leads to higher reduced asthma medication usage (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events · People with asthma (mostly mild or moderate)
1 finding from 1 review
All‐cause mortality · general population including those at moderate to high risk of CVD, mean age between 30 and 75
Systematic screening showed no clear difference in all‐cause mortality compared with no/opportunistic screening (low certainty).
1 finding from 1 review
Stroke · general population including those at moderate to high risk of CVD, mean age between 30 and 75
Systematic screening showed no clear difference in stroke (total) compared with no/opportunistic screening (low certainty).
1 finding from 1 review
Total coronary heart disease · general population including those at moderate to high risk of CVD, mean age between 30 and 75
Systematic screening showed no clear difference in coronary heart disease (total) compared with no/opportunistic screening (low certainty).
1 finding from 1 review
Cholesterol mg/dL · general population including those at moderate to high risk of CVD, mean age between 30 and 75
1 finding from 1 review
Systolic blood pressure · general population including those at moderate to high risk of CVD, mean age between 30 and 75
1 finding from 1 review
Diastolic blood pressure · general population including those at moderate to high risk of CVD, mean age between 30 and 75
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Median (mean) time to use of rescue medication · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Number of women requiring rescue medication · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Participants with ≥ 1 adverse event following a single dose, and after 3 to 5 days · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Participants with a serious adverse event following a single dose, and after 3 to 5 days · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Mutans streptococci prevalence (presence/absence) · Children and adolescents below 18 years at study start (included studies: children from birth to 15 years), with mixed, permanent or…
It is very uncertain whether chlorhexidine gel (0.12%) changes mutans streptococci prevalence (presence/absence) compared with no treatment (very low certainty).
1 finding from 1 review
Chlorhexidine oral product (one formulation/concentration) vs Another chlorhexidine formulation, concentration or application frequency
Outcome not reported · Children and adolescents below 18 years at study start (included studies: children from birth to 15 years), with mixed, permanent or…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Adverse events · Children and adolescents below 18 years at study start (included studies: children from birth to 15 years), with mixed, permanent or…
1 finding from 1 review